- Lexaria
Bioscience is a company dedicated to developing effective oral ingestion
methods for drug substances that rival the rapid-delivery qualities of
more health-dangerous inhaled-drug products.
- Inhalation
is a particularly popular method of using tobacco and cannabis products,
despite government warnings about the scientifically established dangers
of doing so
- Lexaria
has been boosting its profile and revenue potential through licensing
agreements with other companies
- Lexaria
recently announced a licensing agreement with Cannadips CBD-maker The
Boldt Runners Corporation
- The
agreement grants Cannadips CBD use of Lexaria’s DehydraTECH IP to improve
the speed of its effectiveness and to combat the throat irritation that
can accompany use of terpene-rich multi spectrum oils
Drug product consumption innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has
announced a trade agreement that continues to advance the company’s
revenue-building efforts through licensing its technology to other product
manufacturers that can benefit from Lexaria’s DehydraTECH™ oral drug delivery
IP.
The agreement announced recently provides Cannadips CBD with
exclusive access rights to Lexaria’s technology for the U.S. market for 10
years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting,
high-absorption technology with options to expand the license to Europe,
Mexico, and Canada and to renew the license for an additional five years (http://ibn.fm/8hoPO).
“This combination of superior science from Lexaria and a
unique and strong branded proposition that Cannadips offers with its CBD pouch
platform is a winning combination We are excited to be developing a category of
products with best in class science to provide adult consumers the simple
choice of a better product and a better alternative to tobacco and nicotine,”
Lexaria board member Brian Quigley, who is also an adviser to The Boldt Runners
Corporation (Cannadips), stated in a news release.
Lexaria has made its mission the development of swallowed
drug substance consumption methods that approximate the rapid effectiveness of
smoking or vaping, for example, while avoiding the dangers such drug inhalation
can cause to users’ lungs. Those dangers gained new visibility during the past
year as thousands of vape users fell seriously ill or died after inhaling
products containing cannabis or nicotine deemed safer than tobacco
smokes (http://ibn.fm/TlRbK).
The need for Lexaria’s IP has become evident as drug
inhalation has become popular and has remained so despite science’s development
of the means to demonstrate the dangers of smoked products, including cancers,
on users’ lungs (http://ibn.fm/gVfND).
Orally ingested medications and wellness products have in general been slower
to act effectively on the user than inhaled substances and may ultimately enter
the bloodstream in a more dilute measure than originally intended because of
the body’s digestive screening mechanisms.
DehydraTECH has demonstrated its ability to speed its drug
substance payloads to the bloodstream at rates much faster than un-enhanced
oral ingestion. A new formulation of DehydraTECH has nearly doubled its rate of
effectiveness, showing in lab testing that it can deliver cannabidiol (CBD)
into the bloodstream at a rate 811 percent higher than generic industry control
formulations, carrying 1,937 percent more CBD across the blood-brain barrier
than generic industry control formulations (http://ibn.fm/wWvR4).
The body’s natural blood-brain barrier defense system
protects our brain tissue from foreign substances, but also proves to be a
deterrent for most small-molecule drugs that aim to enhance wellness through
the central nervous system.
Cannadips’ American hemp-derived CBD pouches are an ideal
product for pairing with DehydraTECH, offering 15 pouches with 10 mg of CBD
(and no tobacco) each for oral delivery in tins similar in appearance to
chewing tobacco. According to Lexaria’s news release, Cannadips uses
terpene-rich multi spectrum oils as base ingredients that can cause some throat
irritation. While some other products cut their terpenes to avoid the problem,
DehydraTECH allows Cannadips to reduce the throat irritation while maintaining
the entourage effect derived from multi-spectrum oils.
The Cannadips brand is being distributed nationally,
including through Circle K convenience outlets, and are in about 5,000 stores
in the United States with more in Europe.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
